FDA approves breakthrough Alzheimer’s drug Lecanemab

Drug works with the body's immune system to clear amyloid protein buildup from the brain

The US Food and Drug Administration (FDA) has approved Lecanemab, a breakthrough drug to treat Alzheimer's, that is manufactured by biotechnology companies Biogen and Eisai.

The drug is an intravenously administered humanized monoclonal antibody that targets amyloid, the toxic protein in the brain linked to the cognitive disease.